Published in Clin Mol Hepatol on September 25, 2016
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg (1993) 3.91
Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut (2008) 3.65
How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol (2013) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int (2013) 2.53
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33
Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg (2008) 2.31
Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl (2008) 2.22
The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol (2011) 2.12
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy: a world-wide survey. Liver Transpl (2013) 2.00
Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant (2010) 1.93
Hepatic transplantation for primary and metastatic cancers of the liver. Surgery (1991) 1.93
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol (2012) 1.84
Short- and long-term donor morbidity in right lobe living donor liver transplantation: 91 consecutive cases in a European Center. Am J Transplant (2011) 1.70
Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation (2009) 1.69
Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl (2008) 1.68
Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg (2016) 1.52
Liver transplantation for hepatocellular carcinoma. Ann Surg (2001) 1.46
Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant (2012) 1.44
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res (2007) 1.43
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer (2014) 1.38
Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med (2009) 1.30
Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant (2009) 1.27
Indications for liver transplantation in hepatobiliary malignancy. Hepatology (1994) 1.23
Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg (2001) 1.21
Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation (2011) 1.18
Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery (2013) 1.17
Live donors in liver transplantation. Gastroenterology (2008) 1.17
Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology (2014) 1.15
The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl (2006) 1.15
18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant (2009) 1.12
Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant (2009) 1.11
Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant (2014) 1.11
Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci (2013) 1.06
A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery (2007) 1.05
Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl (2011) 1.04
Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc (2005) 1.02
Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl (2012) 1.01
Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2012) 1.01
Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer (2014) 1.00
Criteria for liver transplantation for HCC: what should the limits be? J Hepatol (2011) 1.00
Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg (2010) 0.99
Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation (2013) 0.99
Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl (2008) 0.98
Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 0.97
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res (2012) 0.96
Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol (2010) 0.92
Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg (2010) 0.92
Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant (2011) 0.91
Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther (2014) 0.90
Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int (2014) 0.90
(18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int (2012) 0.89
Living donor liver transplantation. Curr Opin Organ Transplant (2014) 0.87
Predictors of microscopic portal vein invasion by hepatocellular carcinoma: measurement of portal perfusion defect area ratio. J Gastroenterol Hepatol (2009) 0.86
Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol (2015) 0.85
Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol (2012) 0.85
Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int J Hepatol (2012) 0.84
Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol (2015) 0.83
Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis (2007) 0.83
Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma. Transplantation (2015) 0.83
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci (2014) 0.82
Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci (2009) 0.81
Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.80
Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol (2015) 0.80
Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc (2014) 0.78
Section 4. Further expanding the criteria for HCC in living donor liver transplantation: the Tokyo University experience. Transplantation (2014) 0.78
Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis. J Surg Oncol (2015) 0.77
Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant (2016) 0.77
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol (2016) 0.76
Usefulness of preoperative C-reactive protein and alpha-fetoprotein levels for prognostication of patients with hepatocellular carcinoma after living donor liver transplantation. Hepatogastroenterology (2015) 0.76
A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. Korean J Intern Med (2014) 0.83
Histopathologic factors affecting tumor recurrence after hepatic resection in colorectal liver metastases. Ann Surg Treat Res (2014) 0.82
Long term outcomes of pediatric liver transplantation according to age. J Korean Med Sci (2014) 0.81
Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clin Mol Hepatol (2014) 0.80
A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients. Ann Surg Treat Res (2014) 0.80
Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. Liver Int (2015) 0.79
Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy? Korean J Hepatobiliary Pancreat Surg (2011) 0.79
Optimal tailored screening protocol after living donor liver transplantation for hepatocellular carcinoma. J Korean Med Sci (2014) 0.78
Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med (2016) 0.78
Living donor liver transplantation for an infant with osteogenesis imperfecta and intrahepatic cholestasis: report of a case. J Korean Med Sci (2014) 0.78
Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease. Hepatol Res (2015) 0.78
Heterogeneous living donor hepatic fat distribution on MRI chemical shift imaging. Ann Surg Treat Res (2015) 0.76
Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg (2015) 0.76
Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol (2014) 0.76
Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5'-UTR of TRIM22. Gut (2017) 0.76
Nuclear Expression of Hepatitis B Virus X Protein Is Associated with Recurrence of Early-Stage Hepatocellular Carcinomas: Role of Viral Protein in Tumor Recurrence. J Pathol Transl Med (2016) 0.75
The correlation between preoperative volumetry and real graft weight: comparison of two volumetry programs. Ann Surg Treat Res (2017) 0.75
Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci (2015) 0.75
Fatigue and related factors after liver transplantation. Korean J Hepatobiliary Pancreat Surg (2015) 0.75
Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy. J Pathol Transl Med (2016) 0.75
Metastatic follicular struma ovarii complicating pregnancy: a case report and review of the literature. Korean J Hepatobiliary Pancreat Surg (2012) 0.75
Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume. J Korean Med Sci (2014) 0.75
Preparation for high altitude expedition and changes in cardiopulmonary and biochemical laboratory parameters with ascent to high altitude in transplant patients and live donors. Clin Transplant (2015) 0.75
Simple ellipsoid reconstruction technique for a hypoplastic portal vein during pediatric liver transplantation. Liver Transpl (2016) 0.75
Contrast-Enhanced Ultrasound Using Perfluorobutane-Containing Microbubbles in the Assessment of Liver Allograft Damage: An Exploratory Prospective Study. Ultrasound Med Biol (2016) 0.75
Identification of a safe and adequate division point of the left-sided bile duct with magnetic resonance cholangiography during donor left lateral sectionectomy. Surgery (2015) 0.75
Delayed transplantation may affect intellectual ability in children. Pediatr Int (2017) 0.75
Effect of PNPLA3 I148M Polymorphism on Histologically Proven Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. Hepatol Res (2017) 0.75